At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 157 enrolled
Drug / intervention
PS-Omega3 +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment
In Brief
A Phase 4 clinical trial evaluating PS-Omega3 and Placebo for Age Associated Memory Impairment. Completed, enrolled 157 participants across 1 site.
Detailed Summary
The primary objective of this trial is to assess the ability of an oral administration of Phosphatidylserine-Omega3 to improve attention and memory complaints in comparison to placebo in age associated memory impaired subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Associated Memory Impairment
CountriesIsrael
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartApr 2007
Primary CompletionJun 2008
Study CompletionSep 2008
TodayJul 2026
First PostedFeb 21, 2007
Enrollment StartApr 1, 2007
Primary CompletionJun 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.4 years ago
Interventions
PS-Omega3dietary
Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
Placebodietary
Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk